Pharmaron Beijing Co Ltd (300759) - Net Assets

Latest as of September 2025: CN¥15.18 Billion CNY

Based on the latest financial reports, Pharmaron Beijing Co Ltd (300759) has net assets worth CN¥15.18 Billion CNY as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥25.80 Billion) and total liabilities (CN¥10.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥15.18 Billion
% of Total Assets 58.84%
Annual Growth Rate 49.3%
5-Year Change 59.2%
10-Year Change 8344.3%
Growth Volatility 282.91

Pharmaron Beijing Co Ltd - Net Assets Trend (2014–2024)

This chart illustrates how Pharmaron Beijing Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Pharmaron Beijing Co Ltd (2014–2024)

The table below shows the annual net assets of Pharmaron Beijing Co Ltd from 2014 to 2024.

Year Net Assets Change
2024-12-31 CN¥14.22 Billion +7.44%
2023-12-31 CN¥13.24 Billion +22.12%
2022-12-31 CN¥10.84 Billion +5.29%
2021-12-31 CN¥10.30 Billion +15.24%
2020-12-31 CN¥8.93 Billion +13.98%
2019-12-31 CN¥7.84 Billion +234.68%
2018-12-31 CN¥2.34 Billion +16.50%
2017-12-31 CN¥2.01 Billion +14.00%
2016-12-31 CN¥1.76 Billion +946.97%
2015-12-31 CN¥168.43 Million -34.78%
2014-12-31 CN¥258.25 Million --

Equity Component Analysis

This analysis shows how different components contribute to Pharmaron Beijing Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 660818506202.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥6.44 Billion 47.31%
Common Stock CN¥1.78 Billion 13.06%
Other Components CN¥5.40 Billion 39.64%
Total Equity CN¥13.62 Billion 100.00%

Pharmaron Beijing Co Ltd Competitors by Market Cap

The table below lists competitors of Pharmaron Beijing Co Ltd ranked by their market capitalization.

Company Market Cap
Shin Kong Financial Holding Co Ltd
TW:2888
 		$6.58 Billion
The Swatch Group AG
F:UHRA
 		$6.59 Billion
Rakuten Bank, Ltd.
F:N5G
 		$6.60 Billion
China Oilfield Services Ltd Class A
SHG:601808
 		$6.61 Billion
Samsung Engineering
KO:028050
 		$6.58 Billion
Guangzhou Friendship Group Co Ltd
SHE:000987
 		$6.58 Billion
Ono Pharmaceutical Co. Ltd
MU:ON4
 		$6.58 Billion
Chengtun Mining Group Co Ltd
SHG:600711
 		$6.58 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharmaron Beijing Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 12,556,797,361 to 13,619,333,910, a change of 1,062,536,549 (8.5%).
  • Net income of 1,793,350,821 contributed positively to equity growth.
  • Dividend payments of 542,234,339 reduced retained earnings.
  • Share repurchases of 285,906,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥1.79 Billion +13.17%
Dividends Paid CN¥542.23 Million -3.98%
Share Repurchases CN¥285.91 Million -2.1%
Other Changes CN¥97.33 Million +0.71%
Total Change CN¥- 8.46%

Book Value vs Market Value Analysis

This analysis compares Pharmaron Beijing Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.97x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 59.64x to 3.97x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-12-31 CN¥0.51 CN¥30.47 x
2015-12-31 CN¥0.33 CN¥30.47 x
2016-12-31 CN¥2.33 CN¥30.47 x
2017-12-31 CN¥2.25 CN¥30.47 x
2018-12-31 CN¥3.80 CN¥30.47 x
2019-12-31 CN¥11.83 CN¥30.47 x
2020-12-31 CN¥11.23 CN¥30.47 x
2021-12-31 CN¥12.80 CN¥30.47 x
2022-12-31 CN¥5.94 CN¥30.47 x
2023-12-31 CN¥7.07 CN¥30.47 x
2024-12-31 CN¥7.68 CN¥30.47 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharmaron Beijing Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 13.17%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 14.61%
  • • Asset Turnover: 0.51x
  • • Equity Multiplier: 1.76x
  • Recent ROE (13.17%) is below the historical average (14.86%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 8.13% 2.66% 0.85x 3.61x CN¥-4.83 Million
2015 43.84% 6.55% 0.96x 6.97x CN¥57.00 Million
2016 10.03% 10.83% 0.58x 1.59x CN¥569.56K
2017 11.56% 10.06% 0.59x 1.96x CN¥31.09 Million
2018 14.30% 11.45% 0.63x 1.99x CN¥100.15 Million
2019 7.05% 14.56% 0.38x 1.28x CN¥-229.51 Million
2020 13.22% 22.84% 0.43x 1.34x CN¥285.35 Million
2021 16.40% 22.31% 0.40x 1.82x CN¥648.10 Million
2022 13.03% 13.39% 0.50x 1.94x CN¥319.74 Million
2023 12.75% 13.88% 0.44x 2.11x CN¥345.42 Million
2024 13.17% 14.61% 0.51x 1.76x CN¥431.42 Million

Industry Comparison

This section compares Pharmaron Beijing Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,683,796,589
  • Average return on equity (ROE) among peers: 44.88%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pharmaron Beijing Co Ltd (300759) CN¥15.18 Billion 8.13% 0.70x $6.58 Billion
Shenzhen CAU Technology Co Ltd (000004) $284.00 Million 14.35% 1.72x $72.84 Million
Pacific Shuanglin Bio pharmacy Co Ltd (000403) $9.92 Million 348.80% 166.25x $1.80 Billion
Nanhua Bio Medicine Co Ltd (000504) $304.67 Million -9.25% 1.53x $473.27 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $879.72 Million 0.87% 0.09x $456.49 Million
Chengzhi Shareholding Co Ltd (000990) $663.54 Million 6.09% 0.18x $1.90 Billion
Hualan Biological EngineeringInc (002007) $94.10 Million 30.66% 1.57x $4.02 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $69.03 Million 26.90% 0.89x $1.21 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252) $11.73 Billion 13.75% 0.13x $5.54 Billion
Baolingbao Biology Co Ltd (002286) $1.53 Billion 3.25% 0.38x $548.54 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $1.28 Billion 13.36% 0.06x $1.95 Billion

About Pharmaron Beijing Co Ltd

SHE:300759 China Biotechnology
Market Cap
$6.58 Billion
CN¥44.99 Billion CNY
Market Cap Rank
#2828 Global
#355 in China
Share Price
CN¥30.47
Change (1 day)
-2.93%
52-Week Range
CN¥22.22 - CN¥35.90
All Time High
CN¥10080.27
Categories
Companies in China Biotechnology
About

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more